← Back to Search

LSD1 Inhibitor

Sp-2577 for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by Salarius Pharmaceuticals, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at protocol defined time points from start of treatment through end of treatment, up to approximately 24 months
Awards & highlights

Summary

Phase 1, open-label, non-randomized dose finding study of SP-2577 in patients with advanced solid tumors.

Eligible Conditions
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at protocol defined time points from start of treatment through end of treatment, up to approximately 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and at protocol defined time points from start of treatment through end of treatment, up to approximately 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety and tolerability of SP-2577
Secondary study objectives
Changes in serum hemoglobin F concentrations
Changes in the molecular signatures of the tumor
Characterization of pharmacokinetics of SP-2577 (area under the concentration time profile)
+9 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Sp-2577Experimental Treatment1 Intervention
Twice-daily administration of oral SP-2577
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SP-2577 Seclidemstat
2019
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

Salarius Pharmaceuticals, LLCLead Sponsor
4 Previous Clinical Trials
132 Total Patients Enrolled
~4 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top